Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

Abstract: Provided herein are compositions and methods comprising immunogenic polypeptides related to the prevention and treatment of Epstein Ban vims infection and related pathologies.

Abstract: Disclosed are compositions and methods for targeted treatment of cancer, such as HPV-associated cancer. In particular, modified T cell receptor (TCR) T cells are disclosed that can be used with adoptive cell transfer to target and kill cancer cells with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with HPV-associated cancer that involves adoptive transfer of the disclosed TCR-T cells.

Abstract: Disclosed herein is the use of a first population of allogeneic T-cells recognizing a first EBV epitope, and a second allogeneic population recognizing a second EBV epitope in the treatment of EBV-associated disorders. Also disclosed is the use of a population of allogeneic T-cells recognizing an EBV antigen in combination with a further therapeutic agent such as an immunotherapeutic agent, a MAPK, BET or MEK. pathway inhibitor for treating EBV-associated disease.

Abstract: Provided herein are methods and compositions related to polyomavirus epitopes useful in the treatment of cancer or a polyomavirus infection.

Abstract: Disclosed are T-cells that are positive for CD49f and which have an enhanced function compared to CD49f? cells. Methods of isolation of CD49f+ T-cells, as well as compositions and kits thereof are also disclosed. Additionally, enriched CD49f+T-cell populations have an increased proliferative potential, long-term survival and significantly improved efficacy in an adoptive therapeutic setting. The CD49f+ T-cells and CD49f+ T-cell enriched T-cell populations are useful in a range of applications, including for use in treating or inhibiting the development of diseases with immune dysfunction and methods of assessing risk of disease and potential responsiveness in immunotherapy. CD 19 CAR-T cells derived from CD49f+ T-cells and their use in a method of treatment of cancer is also disclosed.

Abstract: Provided herein are methods for preparing and characterizing CTL cultures and preparations. Also provided herein are methods of determining the presence or absence of trace amounts of viral vectors following the preparation of CTLs.

Abstract: Provided herein are compositions and methods related to a multivirus-specific T cell immunotherapy.

Abstract: Provided herein are compositions and methods related to the treatment of an autoimmune disease in a subject.

Abstract: Provided herein are methods and compositions related to the selection T cells and/or subjects for adoptive immunotherapy based on the expression of one or more biomarkers.

Abstract: Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and/or therapeutic immunotherapy based on T cell epitopes (e.g., CMV epitopes) that are recognized by cytotoxic T cells (CTLs) and can be employed in the prevention and/or treatment of CMV infection, reactivation, and/or disease (e.g., CMV-associated end organ disease), especially in solid organ transplant recipients.

Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

Abstract: Provided herein are compositions and methods related to the multivirus-specific T cell immunotherapy.

Abstract: Provided herein are methods and compositions related to the selection T cells and/or subjects for adoptive immunotherapy based on the expression of one or more biomarkers.

Abstract: Provided herein are compositions and methods related to the treatment of an autoimmune disease in a subject.

Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

Abstract: Provided herein are compositions and methods related to the treatment of an HPV infection and/or cancer in a subject.

Abstract: Provided herein are compositions and methods related to the treatment of a CMV infection and/or cancer in a subject.

Abstract: A recombinant, humanized antibody or antibody fragment that is capable of at least partly preventing or inhibiting Epstein Barr Virus gp350 binding to a human cell. The antibody may be useful for passively immunizing humans against Epstein Barr Virus and/or treating or preventing Epstein Barr Virus-associated diseases, disorders or conditions. The antibody or antibody fragment may also be used to detect Epstein Barr Virus.

Abstract: Provided herein are methods and compositions related to polyomavirus epitopes useful in the treatment of cancer or a polyomavirus infection.